Diabetes Care, Vol 23, Issue 4 510-517, Copyright © 2000 by American Diabetes Association

ARTICLES

Patterns of quantitative sensation testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy: a study of three cohorts. Nerve growth factor study group

PJ Dyck, PJ Dyck, TS Larson, PC O'Brien and JA Velosa
Peripheral Neuropathy Research Center, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA. dyck.peterv@mayo.edu

OBJECTIVE: To test quantitative sensation testing (QST) patterns of hypoesthesia and hyperalgesia as indicators of diabetic polyneuropathy (DPN) and its severity RESEARCH DESIGN AND METHODS: We used Computer-Assisted Sensory Examination IV; characterized the QST results of the foot of each patient in three diabetic cohorts (approximately 1,500 patients) as hyperesthetic (< or = 2.5th percentile), low-normal (2.5th-50th percentiles), high-normal (50th-97.5th percentiles), or hypoesthetic (> or = 97.5th percentile); and tested associations with symptoms, impairments, and test abnormalities. RESULTS: Overall neuropathic impairment was most severe in the pancreas-renal transplant and nerve growth factor cohorts, but it was much less severe in the population-based Rochester Diabetic Neuropathy Study (RDNS) cohort. The frequency distribution of sensory abnormalities mirrored this difference. When the QST spectra of diabetic cohorts were compared with those of the control subject cohort for vibration and cooling sensations, the only abnormality observed was hypoesthesia, which was expressed as an increased number of subjects with values at or above the 97.5th percentile or by an increased percentage of cases with high-normal values. Symptoms and impairments of DPN were significantly more frequent in the subjects with values at or above the 97.5th percentile than in the subjects whose values were between the 50th and 97.5th percentiles. For heat pain (HP) sensation thresholds (intermediate pain severity [HP:5], pain threshold [HP:0.5], and pain-stimulus response slope [HP:5-0.5]), an increased frequency of both hypoalgesia and hyperalgesia was observed (especially in the RDNS cohort). Steeper pain-stimulus response slopes were significantly associated with sensory symptoms, including severity of pain. CONCLUSIONS: 1) Decreased vibratory sensation (hypoesthesia) appears to be characteristic of mild DPN, whereas panmodality hypoesthesia is characteristic of severe DPN. 2) A shift of vibratory and cold detection thresholds (and also of attributes of nerve conduction and a measure of autonomic dysfunction) from low-normal (2.5th-50th percentiles) to high-normal (50th-97.5th percentiles) appears to precede overt expression of DPN and to thereby provide evidence of subclinical abnormality 3) Heat stimulus-induced hyperesthesia (low thresholds) occurs especially in mild DPN, and, because it correlates with DPN symptoms and impairments, it must be attributed to hyperalgesia rather than to supersensitivity Therefore, hypoalgesia or hyperalgesia may be an indicator of early DPN.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				I. G. Obrosova, V. R. Drel, C. L. Oltman, N. Mashtalir, J. Tibrewala, J. T. Groves, and M. A. Yorek Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1645 - E1655. [Abstract] [Full Text] [PDF]

				H. Forssell, O. Tenovuo, P. Silvoniemi, and S. K. Jaaskelainen Differences and similarities between atypical facial pain and trigeminal neuropathic pain Neurology, October 2, 2007; 69(14): 1451 - 1459. [Abstract] [Full Text] [PDF]

				L. Zhou, D. W. Kitch, S. R. Evans, P. Hauer, S. Raman, G. J. Ebenezer, M. Gerschenson, C. M. Marra, V. Valcour, R. Diaz-Arrastia, et al. Correlates of epidermal nerve fiber densities in HIV-associated distal sensory polyneuropathy Neurology, June 12, 2007; 68(24): 2113 - 2119. [Abstract] [Full Text] [PDF]

				M. J. Stevens, F. Li, V. R. Drel, O. I. Abatan, H. Kim, D. Burnett, D. Larkin, and I. G. Obrosova Nicotinamide Reverses Neurological and Neurovascular Deficits in Streptozotocin Diabetic Rats J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 458 - 464. [Abstract] [Full Text] [PDF]

				V. R. Drel, N. Mashtalir, O. Ilnytska, J. Shin, F. Li, V. V. Lyzogubov, and I. G. Obrosova The Leptin-Deficient (ob/ob) Mouse: A New Animal Model of Peripheral Neuropathy of Type 2 Diabetes and Obesity Diabetes, December 1, 2006; 55(12): 3335 - 3343. [Abstract] [Full Text] [PDF]

				D. M. Simpson, D. Kitch, S. R. Evans, J. C. McArthur, D. M. Asmuth, B. Cohen, K. Goodkin, M. Gerschenson, Y. So, C. M. Marra, et al. HIV neuropathy natural history cohort study: Assessment measures and risk factors Neurology, June 13, 2006; 66(11): 1679 - 1687. [Abstract] [Full Text] [PDF]

				C. L. Cherry, R. L. Skolasky, L. Lal, J. Creighton, P. Hauer, S. P. Raman, R. Moore, K. Carter, D. Thomas, G. J. Ebenezer, et al. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort Neurology, March 28, 2006; 66(6): 867 - 873. [Abstract] [Full Text] [PDF]

				R. R. Edwards Individual differences in endogenous pain modulation as a risk factor for chronic pain Neurology, August 9, 2005; 65(3): 437 - 443. [Abstract] [Full Text] [PDF]

				K. Uehara, S.-I. Yamagishi, S. Otsuki, S. Chin, and S. Yagihashi Effects of Polyol Pathway Hyperactivity on Protein Kinase C Activity, Nociceptive Peptide Expression, and Neuronal Structure in Dorsal Root Ganglia in Diabetic Mice Diabetes, December 1, 2004; 53(12): 3239 - 3247. [Abstract] [Full Text] [PDF]

				C.-T. Shun, Y.-C. Chang, H.-P. Wu, S.-C. Hsieh, W.-M. Lin, Y.-H. Lin, T.-Y. Tai, and S.-T. Hsieh Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairments Brain, July 1, 2004; 127(7): 1593 - 1605. [Abstract] [Full Text] [PDF]

				A. J.M. Boulton, R. A. Malik, J. C. Arezzo, and J. M. Sosenko Diabetic Somatic Neuropathies Diabetes Care, June 1, 2004; 27(6): 1458 - 1486. [Full Text] [PDF]

				M. J. Hilz, M. Brys, H. Marthol, B. Stemper, and M. Dutsch Enzyme replacement therapy improves function of C-, A{delta}-, and A{beta}-nerve fibers in Fabry neuropathy Neurology, April 13, 2004; 62(7): 1066 - 1072. [Abstract] [Full Text] [PDF]

				A. Pestronk, J. Florence, T. Levine, M. T. Al-Lozi, G. Lopate, T. Miller, I. Ramneantu, W. Waheed, and M. Stambuk Sensory exam with a quantitative tuning fork: Rapid, sensitive and predictive of SNAP amplitude Neurology, February 10, 2004; 62(3): 461 - 464. [Abstract] [Full Text] [PDF]

				N. I. Spielholz, P. J. Dyck, P. C. O'Brien, M. E. Shy, and E. M. Frohman Quantitative sensory testing: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology, December 9, 2003; 61(11): 1628 - 1630. [Full Text] [PDF]

				P. Petrillo, O. Angelici, S. Bingham, G. Ficalora, M. Garnier, P. F. Zaratin, G. Petrone, O. Pozzi, M. Sbacchi, T. O. Stean, et al. Evidence for a Selective Role of the {delta}-Opioid Agonist [8R-(4bS*,8a{alpha},8a{beta},12b{beta})]7,10-Dimethyl-1-methoxy-11-(2-methylpropyl)oxycarbonyl 5,6,7,8,12,12b-hexahydro-(9H)-4,8-methanobenzofuro[3,2-e]pyrrolo[2,3-g]isoquinoline Hydrochloride (SB-235863) in Blocking Hyperalgesia Associated with Inflammatory and Neuropathic Pain Responses J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1079 - 1089. [Abstract] [Full Text] [PDF]

				M.-M. Backonja Defining Neuropathic Pain Anesth. Analg., September 1, 2003; 97(3): 785 - 790. [Abstract] [Full Text] [PDF]

				A. Shearer, P. Scuffham, A. Gordois, and A. Oglesby Predicted Costs and Outcomes From Reduced Vibration Detection in People With Diabetes in the U.S. Diabetes Care, August 1, 2003; 26(8): 2305 - 2310. [Abstract] [Full Text] [PDF]